Breaking News

GLYC

GlycoMimetics

02/15/23 H.C. Wainwright: GlycoMimetics price target lowered to $8 from $13 at H.C. Wainwright

08/03/22 H.C. Wainwright: GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright

04/28/22 Roth Capital: Roth remains bullish on GlycoMimetics after corporate updates call

Clear This Search Refresh Search

Wednesday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
On The Fly	Fly Intel: Pre-market Movers » 09:01 03/29/23 03/29 09:01 03/29/23 09:01 LCID Lucid Group $7.56 / -0.58 (-7.13%) , UNF UniFirst $192.81 / +1.12 (+0.58%) , KC Kingsoft Cloud $6.11 / -0.19 (-3.02%) , LULU Lululemon $320.74 / +3.44 (+1.08%) , MU Micron $59.40 / -0.41 (-0.69%) , CONN Conn's $5.41 / -0.33 (-5.75%) , GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) , SLGC SomaLogic $2.35 / -0.01 (-0.42%) , MINM Minim / + Check out this morning's… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options UNF SLGC MU MINM LULU LCID KC GLYC CONN UNF UniFirst $192.81 / +1.12 (+0.58%) 02/08/23 UniFirst to acquire Clean Uniform for $300M 10/25/22 UniFirst increases quarterly common stock dividend to 31c per share SLGC SomaLogic $2.35 / -0.01 (-0.42%) 03/13/23 SomaLogic delivers 28M proteomic data points on CKB samples 01/05/23 Cathie Wood's ARK Investment bought 415.4K shares of SomaLogic today 01/04/23 Cathie Wood's ARK Investment bought 313K shares of SomaLogic today 01/03/23 Cathie Wood's ARK Investment bought 288K shares of SomaLogic today MU Micron $59.40 / -0.41 (-0.69%) 03/28/23 Micron says now expects overall headcount reduction to approach 15% 03/28/23 Micron says further reducing supply 03/28/23 Micron up 2% after Q2 report 03/02/23 Micron down 3% in pre-market as CFO presents at conference MINM Minim / + 02/09/23 Minim to enhance user experience with launch of Support+ on motosync app 01/31/23 Minim network portfolio launches on HomeDepot.com 12/22/22 Minim launches live shopping experience with HSN 12/07/22 Minim expands e-commerce footprint with OfficeDepot.com LULU Lululemon $320.74 / +3.44 (+1.08%) 03/28/23 Lululemon jumps 9% to $348.97 after Q4 results, FY23 guidance beat estimates 01/12/23 lululemon teams with Nedap to advance RFID technology across stores 01/09/23 Lululemon falls 14% to $282.02 after revising Q4 guidance 12/08/22 Lululemon falls 9% to $340.75 after Q3 results and guidance LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/29/23 Lucid Group to cut workforce by about 18% as part of restructuring plan 03/28/23 Lucid Group down 6% to $7.64 following report of layoffs 03/27/23 Lucid recalls 2022-2023 Lucid Air vehicles for issue with electric motors 02/22/23 Lucid Group down 8% afterhours at $9.14 after Q4 results and 2023 outlook KC Kingsoft Cloud $6.11 / -0.19 (-3.02%) 12/29/22 Kingsoft Cloud announces results of extraordinary general meeting 12/27/22 China stocks rising with borders set to reopen on January 8 12/23/22 PCAOB chair 'applauds' Congressional action to shorten HFCAA timeline GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) 03/10/23 GlycoMimetics considers SVB exposure 'immaterial' 02/15/23 GlycoMimetics:Uproleselan in RR study continues with original even trigger event CONN Conn's $5.41 / -0.33 (-5.75%) 03/29/23 Conn's plans to open 11 new standalone locations in FY24 01/10/23 Conn's extending gains afterhours on WSJ report of acquisition interest, up 13% 01/10/23 Conn's trading resumes 01/10/23 Conn's trading halted, volatility trading pause LCID UNF KC LULU MU CONN GLYC SLGC MINM LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/29/23 BofA Restructuring not positive for growth companies like Lucid, says BofA 03/29/23 Morgan Stanley Other EV startups may need to consider actions like Lucid, says Morgan Stanley 03/02/23 Citi Lucid Group price target lowered to $11.50 from $12 at Citi 02/23/23 R.F. Lafferty Lucid Group price target lowered to $12 from $17 at R.F. Lafferty UNF UniFirst $192.81 / +1.12 (+0.58%) 01/05/23 Baird UniFirst price target raised to $225 from $199 at Baird 05/18/22 Baird UniFirst price target lowered to $195 from $213 at Baird 04/01/22 JPMorgan UniFirst downgraded to sell on missed earnings pattern at JPMorgan 04/01/22 JPMorgan UniFirst downgraded to Underweight from Neutral at JPMorgan KC Kingsoft Cloud $6.11 / -0.19 (-3.02%) 03/13/23 JPMorgan Kingsoft Cloud initiated with a Neutral at JPMorgan 01/09/23 China Renaissance Kingsoft Cloud downgraded to Sell from Hold at China Renaissance 09/07/22 Citi Kingsoft Cloud downgraded to Neutral from Buy at Citi 06/09/22 Citi Kingsoft Cloud price target lowered to $8.50 from $10 at Citi LULU Lululemon $320.74 / +3.44 (+1.08%) 03/29/23 Jefferies Lululemon concerns 'haven't gone away' after Q4 report, says Jefferies 03/29/23 TD Cowen Lululemon price target raised to $500 from $470 at TD Cowen 03/29/23 Baird Lululemon price target raised to $425 from $410 at Baird 03/29/23 BofA Lululemon price target raised to $410 from $380 at BofA MU Micron $59.40 / -0.41 (-0.69%) 03/29/23 Susquehanna Micron price target raised to $90 from $65 at Susquehanna 03/29/23 TD Cowen Micron price target raised to $70 from $66 at TD Cowen 03/29/23 Baird Micron price target raised to $60 from $45 at Baird 03/29/23 Loop Capital Micron results impacted by inventory writedown, says Loop Capital CONN Conn's $5.41 / -0.33 (-5.75%) 12/07/22 Stephens Conn's price target lowered to $9 from $13 at Stephens 04/11/22 Stephens Conn's assumed with an Equal Weight at Stephens GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) 02/15/23 H.C. Wainwright GlycoMimetics price target lowered to $8 from $13 at H.C. Wainwright 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call SLGC SomaLogic $2.35 / -0.01 (-0.42%) 03/29/23 Canaccord SomaLogic price target lowered to $5 from $6 at Canaccord 03/29/23 TD Cowen SomaLogic price target lowered to $7 from $8 at TD Cowen 03/29/23 Stifel SomaLogic price target lowered to $7 from $8 at Stifel 08/16/22 TD Cowen SomaLogic price target lowered to $9 from $11 at Cowen MINM Minim / + UNF SLGC MU MINM LULU LCID KC GLYC CONN UNF UniFirst $192.81 / +1.12 (+0.58%) 03/29/23 UniFirst sees 2023 EPS $5.02-$5.37, consensus $7.55 03/29/23 UniFirst reports Q2 EPS 95c, consensus $1.38 01/04/23 UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.21 01/04/23 UniFirst reports Q1 adjusted EPS $2.21, consensus $1.94 SLGC SomaLogic $2.35 / -0.01 (-0.42%) 03/28/23 SomaLogic sees FY23 revenue $80M-$84M, consensus $92.75M 03/28/23 SomaLogic reports Q4 EPS (26c), consensus (21c) 01/09/23 SomaLogic sees 2022 revenue at high-end of $93M-$98M, consensus $95M 11/14/22 SomaLogic sees FY22 revenue $93M-$98M, consensus $83.02M MU Micron $59.40 / -0.41 (-0.69%) 03/28/23 Micron sees Q3 adjusted EPS ($1.65)-($1.51), consensus (90c) 03/28/23 Micron reports Q2 adjusted EPS ($1.91), consensus (86c) 03/02/23 Micron sees lower margins in fiscal Q3 than previously expected MINM Minim / + 03/29/23 Minim reports Q4 EPS (10c) vs (4c) last year 11/10/22 Minim reports Q3 EPS (9c) vs 4c last year LULU Lululemon $320.74 / +3.44 (+1.08%) 03/28/23 Lululemon sees FY23 EPS $11.50-$11.72, consensus $11.26 03/28/23 Lululemon sees Q1 EPS $1.93-$2.00, consensus $1.64 03/28/23 Lululemon reports Q4 adjusted EPS $4.40, consensus $4.26 03/28/23 Notable companies reporting after market close LCID Lucid Group $7.56 / -0.58 (-7.13%) 02/22/23 Lucid Group reports Q4 EPS (28c), consensus (40c) 02/22/23 Notable companies reporting after market close 11/08/22 Lucid Group reports Q3 EPS (40c), consensus (31c) 11/08/22 Notable companies reporting after market close KC Kingsoft Cloud $6.11 / -0.19 (-3.02%) 03/29/23 Kingsoft Cloud sees Q1 revenue RMB1.85B-RMB2.05B 03/29/23 Kingsoft Cloud reports Q4 EPS (2c), consensus (24c) 11/23/22 Kingsoft Cloud sees Q4 revenue up 1.6%-11.7% sequentially to RMB2.0B-RMB2.2B 11/23/22 Kingsoft Cloud reports Q3 EPS (3c), consensus (23c) GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) 03/29/23 GlycoMimetics reports Q4 EPS (19c), consensus (17c) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) CONN Conn's $5.41 / -0.33 (-5.75%) 03/29/23 Conn's reports Q4 adjusted EPS ($1.53), consensus (87c) 12/06/22 Conn's reports Q3 non-GAAP EPS (78c), consensus (83c) 10/18/22 Conn's withdraws FY23 financial guidance 10/18/22 Conn's sees Q3 revenue down 21%-23%, consensus $326.11M MU LULU LCID KC CONN MU Micron $59.40 / -0.41 (-0.69%) 03/10/23 U.S. to further tighten chip gear export to China restrictions, Bloomberg says 03/10/23 U.S. to further tighten chip gear export to China restrictions, Bloomberg says 01/04/23 China pauses chip industry investments as COVID resurges, Bloomberg reports 12/31/22 Take-Two, Micron had a terrible 2022, could be time to buy, Barron's says LULU Lululemon $320.74 / +3.44 (+1.08%) 09/30/22 Peloton tells Bloomberg resolved dispute with Lululemon over athletic wear 09/29/22 Peloton suit against Lululemon thrown out by court, Bloomberg reports 09/29/22 Lululemon wins dismissal of patent suit by Peloton, Bloomberg reports LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/28/23 Lucid Group to eliminate 18% of workforce, Insider reports 01/30/23 Fuzzy Panda short Lucid Group, calls buyout rumor 'fake news' 01/30/23 Fuzzy Panda says sell Lucid Group on 'fake' buyout rumor 01/27/23 Lucid Group spike attributed to takeout speculation by Betaville KC Kingsoft Cloud $6.11 / -0.19 (-3.02%) 12/22/22 China seen cutting quarantine for inbound overseas travelers, Global Times says CONN Conn's $5.41 / -0.33 (-5.75%) 01/10/23 Franchise Group could go private or may bid to buy Conn's, WSJ reports 01/10/23 Franchise Group eyeing potential deal to acquire Conn's, WSJ says UNF MU LULU LCID KC GLYC CONN UNF UniFirst $192.81 / +1.12 (+0.58%) 01/04/23 What You Missed On Wall Street On Wednesday 01/04/23 What You Missed On Wall Street This Morning MU Micron $59.40 / -0.41 (-0.69%) 03/28/23 Here's what Wall Street is saying about Micron ahead of earnings 03/02/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/10/23 What You Missed On Wall Street On Friday 02/10/23 What You Missed On Wall Street This Morning LULU Lululemon $320.74 / +3.44 (+1.08%) 03/28/23 Fly Intel: After-Hours Movers 03/18/23 Buy/Sell: Wall Street's top 10 stock calls this week 03/16/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/28/23 Buy/Sell: Wall Street's top 10 stock calls this week LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/28/23 What You Missed On Wall Street On Tuesday 02/27/23 What You Missed This Week in EVs and Clean Energy 02/23/23 What You Missed On Wall Street On Thursday 02/23/23 What You Missed On Wall Street This Morning KC Kingsoft Cloud $6.11 / -0.19 (-3.02%) 12/29/22 What You Missed On Wall Street This Morning 11/23/22 What You Missed On Wall Street On Wednesday 11/23/22 What You Missed On Wall Street This Morning GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 11/18/22 Biotech Alert: Searches spiking for these stocks today CONN Conn's $5.41 / -0.33 (-5.75%) 01/11/23 What You Missed On Wall Street On Wednesday 01/11/23 What You Missed On Wall Street This Morning 01/10/23 Fly Intel: After-Hours Movers 12/12/22 Fly Intel: After-Hours Movers 03/29/23 Kingsoft Cloud - KC 03/29/23 GlycoMimetics - GLYC 03/29/23 Minim - MINM 03/29/23 UniFirst - UNF 03/29/23 Conn's - CONN 04/24/23 Lucid Group Inc SLGC MU LULU LCID SLGC SomaLogic $2.35 / -0.01 (-0.42%) 02/03/23 Largest borrow rate increases among liquid names MU Micron $59.40 / -0.41 (-0.69%) 03/28/23 Micron options imply 5.2% move in share price post-earnings 03/07/23 Micron call volume above normal and directionally bullish 03/02/23 Unusually active option classes on open March 2nd 02/23/23 Unusually active option classes on open February 23rd LULU Lululemon $320.74 / +3.44 (+1.08%) 03/28/23 Lululemon options imply 7.2% move in share price post-earnings 01/24/23 Unusually active option classes on open January 24th 01/04/23 Lululemon put volume heavy and directionally bearish 12/21/22 Unusually active option classes on open December 21st LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/29/23 Largest borrow rate increases among liquid names 03/21/23 Largest borrow rate increases among liquid names 02/28/23 Largest borrow rate increases among liquid names 02/27/23 Largest borrow rate increases among liquid names
Earnings	GlycoMimetics reports Q4 EPS (19c), consensus (17c) » 07:10 03/29/23 03/29 07:10 03/29/23 07:10 GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) As of December 31, 2022,… As of December 31, 2022, GlycoMimetics had cash and cash equivalents of $47.9M as compared to $90.3M as of December 31, 2021. In the first quarter, GlycoMimetics raised a total of $28.7M from sales of shares of common stock under its existing ATM facility. "In 2022, we made great strides in our continued organizational evolution, strengthening our leadership team and financial position as we aspire to become a commercial-stage company capable of delivering uproleselan to R/R AML patients in need of innovative new treatment options," said Harout Semerjian, CEO of GlycoMimetics. "Patients continue to live longer in our pivotal Phase 3 study of uproleselan, with duration of median follow-up for the blinded, pooled patient population now at a remarkable 25 months. Our Phase 3 AML trial projects to have the longest duration of median follow-up at time of primary analysis of any study, to our knowledge, previously conducted in this disease area. We remain optimistic and excited about the potential of uproleselan to improve overall survival in R/R AML." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) 03/10/23 GlycoMimetics considers SVB exposure 'immaterial' 02/15/23 GlycoMimetics:Uproleselan in RR study continues with original even trigger event GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) 02/15/23 H.C. Wainwright GlycoMimetics price target lowered to $8 from $13 at H.C. Wainwright 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) GLYC GlycoMimetics $1.40 / -0.01 (-0.71%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 11/18/22 Biotech Alert: Searches spiking for these stocks today 03/29/23 GlycoMimetics - GLYC

Over a week ago
Hot Stocks	GlycoMimetics considers SVB exposure 'immaterial' » 17:08 03/10/23 03/10 17:08 03/10/23 17:08 GLYC GlycoMimetics $1.30 / -0.05 (-3.70%) , SIVB SVB Financial $105.92 / -0.04 (-0.04%) In a regulatory filing,… In a regulatory filing, GlycoMimetics (GLYC) said it currently maintains an account at Silicon Valley Bank (SIVB) holding cash deposits of approximately $2M, which amount the company considers to be immaterial to its liquidity. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options SIVB GLYC SIVB SVB Financial $105.92 / -0.04 (-0.04%) 03/10/23 Savara says exposure to Silicon Valley Bank immaterial 03/10/23 X4 Pharmaceuticals says held about 2.5% of cash deposits at SVB 03/10/23 Cara Therapeutics says it does not hold cash deposits, securities at SVB 03/10/23 Wave Life considers direct SVB exposure 'immaterial' GLYC GlycoMimetics $1.30 / -0.05 (-3.70%) 02/15/23 GlycoMimetics:Uproleselan in RR study continues with original even trigger event GLYC SIVB GLYC GlycoMimetics $1.30 / -0.05 (-3.70%) 02/15/23 H.C. Wainwright GlycoMimetics price target lowered to $8 from $13 at H.C. Wainwright 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call SIVB SVB Financial $105.92 / -0.04 (-0.04%) 03/10/23 Maxim SVB Financial downgraded to Sell from Buy at Maxim 03/10/23 Baird West Coast REITs underperforming on SVB news, says Baird 03/10/23 Stifel Stifel says SVB fallout 'appears limited' across firm's biotech coverage 03/10/23 GLJ Research Sunrun has lost two largest lenders in 90 days, says GLJ Research SIVB GLYC SIVB SVB Financial $105.92 / -0.04 (-0.04%) 01/19/23 SVB Financial reports Q4 EPS $4.62, consensus $5.27 10/20/22 SVB Financial reports Q3 EPS $7.21, consensus $6.95 GLYC GlycoMimetics $1.30 / -0.05 (-3.70%) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) 10 Mar SIVB SIVB SVB Financial $105.92 / -0.04 (-0.04%) 03/10/23 FDIC, Federal Reserve regulators at SVB Financial, Bloomberg reports 03/10/23 SVB could be rescued by government with no deal, WSJ reports 03/10/23 SVB Financial has staff work from home amid talks on next steps, Reuters reports 03/10/23 SVB deposit outflows outpacing sales process, CNBC reports SIVB GLYC SIVB SVB Financial $105.92 / -0.04 (-0.04%) 03/10/23 What You Missed On Wall Street On Friday 03/10/23 What You Missed On Wall Street This Morning 03/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/09/23 What You Missed On Wall Street On Thursday GLYC GlycoMimetics $1.30 / -0.05 (-3.70%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 11/18/22 Biotech Alert: Searches spiking for these stocks today SIVB SIVB SVB Financial $105.92 / -0.04 (-0.04%) 02/02/23 Early notable gainers among liquid option names on February 2nd 01/20/23 Early notable gainers among liquid option names on January 20th 01/19/23 SVB Capital II options imply 7.1% move in share price post-earnings 12/29/22 Early notable gainers among liquid option names on December 29th

Over a month ago
Recommendations	GlycoMimetics price target lowered to $8 from $13 at H.C. Wainwright » 12:14 02/15/23 02/15 12:14 02/15/23 12:14 GLYC GlycoMimetics $1.90 / -2.135 (-52.91%) H.C. Wainwright lowered… H.C. Wainwright lowered the firm's price target on GlycoMimetics to $8 from $13 and keeps a Buy rating on the shares. The analyst cites dilution from the capital raise and a pushing out of the launch expectation for uproleselan for the target drop. ShowHide Related Items >><< Company News Street Research Earnings On The Fly GLYC GlycoMimetics $1.90 / -2.135 (-52.91%) 02/15/23 GlycoMimetics:Uproleselan in RR study continues with original even trigger event 09/06/22 GlycoMimetics appoints Edwin Rock, M.D. as CMO GLYC GlycoMimetics $1.90 / -2.135 (-52.91%) 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call GLYC GlycoMimetics $1.90 / -2.135 (-52.91%) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) GLYC GlycoMimetics $1.90 / -2.135 (-52.91%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 11/18/22 Biotech Alert: Searches spiking for these stocks today
Hot Stocks	GlycoMimetics:Uproleselan in RR study continues with original even trigger event » 08:32 02/15/23 02/15 08:32 02/15/23 08:32 GLYC GlycoMimetics $4.04 / +0.265 (+7.03%) GlycoMimetics announced… GlycoMimetics announced the independent Data Monitoring Committee, DMC, reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory, R/R, acute myeloid leukemia, AML, and recommended the study should continue to the originally planned final overall survival event trigger. "We thank the independent DMC for its recommendation and are strongly encouraged as the blinded pooled survival data continues to show patients living longer than historical benchmarks. Going forward, survival duration for new events in the study will be greater than 14 months since the last patient was randomized, giving us confidence in the potential for uproleselan to improve outcomes for people living with R/R AML," said Harout Semerjian, Chief Executive Officer of GlycoMimetics. "We are proud to be advancing a novel treatment with significant potential to address the urgent unmet medical need in this acute leukemia, and we look forward to continuing the study to the originally planned final overall survival analysis, now expected within the first half of 2024." ShowHide Related Items >><< Company News Street Research Earnings On The Fly GLYC GlycoMimetics $4.04 / +0.265 (+7.03%) 09/06/22 GlycoMimetics appoints Edwin Rock, M.D. as CMO GLYC GlycoMimetics $4.04 / +0.265 (+7.03%) 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call GLYC GlycoMimetics $4.04 / +0.265 (+7.03%) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) GLYC GlycoMimetics $4.04 / +0.265 (+7.03%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 11/18/22 Biotech Alert: Searches spiking for these stocks today
Conference/Events	GlycoMimetics management to meet virtually with Jefferies » 11:51 01/31/23 01/31 11:51 01/31/23 11:51 GLYC GlycoMimetics $2.97 / +0.06 (+2.06%) Healthcare Analyst Song… Healthcare Analyst Song holds a virtual meeting with CEO Semerjian, CFO Hahn, CCO Johnson and CMO Rock on January 31 hosted by Jefferies. ShowHide Related Items >><< Company News Street Research Earnings On The Fly GLYC GlycoMimetics $2.97 / +0.06 (+2.06%) 09/06/22 GlycoMimetics appoints Edwin Rock, M.D. as CMO GLYC GlycoMimetics $2.97 / +0.06 (+2.06%) 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call GLYC GlycoMimetics $2.97 / +0.06 (+2.06%) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) 08/03/22 GlycoMimetics reports Q2 EPS (25c), consensus (28c) GLYC GlycoMimetics $2.97 / +0.06 (+2.06%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 11/18/22 Biotech Alert: Searches spiking for these stocks today
On The Fly	Fly Insider: Terns Pharma, Best Buy among week's notable insider trades » 14:22 01/03/23 01/03 14:22 01/03/23 14:22 CHPT ChargePoint $9.11 / -0.425 (-4.46%) , TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) , GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) , ATHA Athira Pharma $3.34 / +0.175 (+5.54%) , AES AES Corp. $28.24 / -0.52 (-1.81%) , CLH Clean Harbors $113.80 / -0.31 (-0.27%) , BBY Best Buy $80.22 / + (+0.00%) , BGNE BeiGene $225.27 / +5.31 (+2.41%) Welcome to "Fly Insider,"… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TERN GLYC CLH CHPT BGNE BBY ATHA AES TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 08/12/22 Terns Pharmaceuticals announces $65M oversubscribed offering GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) 09/06/22 GlycoMimetics appoints Edwin Rock, M.D. as CMO CLH Clean Harbors $113.80 / -0.31 (-0.27%) 12/22/22 COO of Clean Harbors Gerstenberg sells over $1.9M in company shares 11/02/22 Clean Harbors appoints COO Eric Gerstenberg, CFO Michael Battles as co-CEOs 11/02/22 Clean Harbors sees FY22 adjusted EBITDA $1.01B-$1.03B 10/03/22 Hudson Technologies appoints Bulgarino, Mansy to board of directors CHPT ChargePoint $9.11 / -0.425 (-4.46%) 12/06/22 Vietnam-based EV maker VinFast plans for U.S. IPO 11/08/22 Nikola, ChargePoint announce partnership 10/05/22 ChargePoint announces global charging solution CP6000 10/02/22 Fly Intel: Top five weekend stock stories BGNE BeiGene $225.27 / +5.31 (+2.41%) 12/30/22 BeiGene announces CDE acceptance of tislelizumab sBLA 12/29/22 BeiGene CEO sells $2.16M in common stock 12/13/22 BeiGene says Brukinsa shows superior efficacy versus Imbruvica in study 12/08/22 Phanes Therapeutics announces clinical supply agreement with BeiGene BBY Best Buy $80.22 / + (+0.00%) 11/22/22 Best Buy rises 9.5% 11/22/22 Best Buy jumps 8% to $76.17 after Q3 earnings beat and comps outlook update 11/22/22 Best Buy sees FY23 comparable sales down approximately 10% 11/22/22 Genesco appoints Best Buy CFO Matthew Bilunas to board ATHA Athira Pharma $3.34 / +0.175 (+5.54%) 12/21/22 Athira Pharma announces publication of fosgonimeton preclinical results 12/05/22 Athira Pharma presents preclinical data on ATH-1105 in ALS 11/29/22 Athira Pharma: Data shows fosgonimeton treatment significantly improved NfL 11/16/22 Athira Pharma presents preclinical data on HGF-MET neurotrophic system AES AES Corp. $28.24 / -0.52 (-1.81%) 12/08/22 Air Products, AES Corp. to invest $4B in new Texas green hydrogen facility 12/02/22 AES Corp. raises quarterly dividend 5% to 16.59c per share 10/11/22 AES Corp. dedicates 227 MW, 908 MWh of energy storage projects in California 08/08/22 Fluence Energy appoints Julian Nebreda as CEO, president CHPT TERN GLYC ATHA AES CLH BBY BGNE CHPT ChargePoint $9.11 / -0.425 (-4.46%) 12/22/22 Piper Sandler ChargePoint price target lowered to $13 from $16 at Piper Sandler 12/05/22 DA Davidson ChargePoint price target lowered to $18 from $20 at DA Davidson 12/02/22 R.F. Lafferty ChargePoint price target lowered to $28 from $34 at R.F. Lafferty 12/02/22 Oppenheimer ChargePoint price target lowered to $26 from $40 at Oppenheimer TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call ATHA Athira Pharma $3.34 / +0.175 (+5.54%) 10/17/22 JMP Securities Athira upgraded to Outperform at JMP after DMC recommends study continue 10/17/22 JMP Securities Athira Pharma upgraded to Outperform from Market Perform at JMP Securities 09/28/22 Mizuho Mizuho says Biogen data will serve as catalyst for these stocks 07/06/22 Mizuho Athira Pharma initiated with a Buy at Mizuho AES AES Corp. $28.24 / -0.52 (-1.81%) 12/01/22 Argus AES Corp. price target raised to $31 from $29 at Argus 11/09/22 Citi AES Corp. price target raised to $30 from $27 at Citi 11/07/22 Susquehanna AES Corp. price target raised to $33 from $30 at Susquehanna 08/18/22 Morgan Stanley AES Corp. price target raised to $32 from $29.50 at Morgan Stanley CLH Clean Harbors $113.80 / -0.31 (-0.27%) 11/03/22 UBS Clean Harbors downgraded to Neutral from Buy at UBS 11/03/22 Baird Clean Harbors price target raised to $155 from $150 at Baird 09/02/22 Stifel Clean Harbors price target raised to $145 from $127 at Stifel 08/04/22 BMO Capital Clean Harbors price target raised to $124 from $104 at BMO Capital BBY Best Buy $80.22 / + (+0.00%) 12/19/22 Credit Suisse Best Buy initiated with a Neutral at Credit Suisse 12/14/22 BofA Best Buy downgraded to Underperform at BofA on challenging demand environment 12/14/22 BofA Best Buy downgraded to Underperform from Neutral at BofA 12/12/22 Goldman Sachs Best Buy upgraded to Neutral from Sell at Goldman Sachs BGNE BeiGene $225.27 / +5.31 (+2.41%) 11/10/22 TD Cowen BeiGene price target raised to $213 from $200 at Cowen 10/13/22 Guggenheim BeiGene upgraded to Buy at Guggenheim on higher conviction in Brukinsa 10/13/22 Guggenheim BeiGene upgraded to Buy from Neutral at Guggenheim 10/12/22 SVB Securities BeiGene upgraded to Outperform at SVB Securities on positive Brukinsa data TERN GLYC CLH CHPT BGNE BBY ATHA AES TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) 08/03/22 GlycoMimetics reports Q2 EPS (25c), consensus (28c) CLH Clean Harbors $113.80 / -0.31 (-0.27%) 11/02/22 Clean Harbors reports Q3 adjusted EPS $2.43, consensus $2.11 08/03/22 Clean Harbors sees FY22 EBITDA $975M-$1.005B 08/03/22 Clean Harbors reports Q2 EPS $2.44 consensus $1.48 CHPT ChargePoint $9.11 / -0.425 (-4.46%) 12/01/22 ChargePoint narrows FY23 revenue view to $475M-$485M from $450M-$500M 12/01/22 ChargePoint sees Q4 revenue $160M-$170M, consensus $160.91M 12/01/22 ChargePoint reports Q3 EPS (25c), consensus (19c) 12/01/22 Notable companies reporting after market close BGNE BeiGene $225.27 / +5.31 (+2.41%) 11/09/22 BeiGene reports Q3 EPS ($5.39), consensus ($4.01) 08/04/22 BeiGene reports Q2 EPS $5.56 vs. $5.23 last year BBY Best Buy $80.22 / + (+0.00%) 11/22/22 Best Buy reports Q3 EPS $1.38, consensus $1.03 11/21/22 Notable companies reporting before tomorrow's open 08/30/22 Best Buy reports Q2 EPS$1.54, consensus $1.27 ATHA Athira Pharma $3.34 / +0.175 (+5.54%) 11/10/22 Athira Pharma reports Q3 EPS (53c), consensus (63c) 08/15/22 Athira Pharma reports Q2 EPS (65c), consensus (64c) AES AES Corp. $28.24 / -0.52 (-1.81%) 11/04/22 AES Corp. sees FY22 EPS at high end of $1.55-$1.65 range, consensus $1.61 11/04/22 AES Corp. reports Q3 adjusted EPS 63c, consensus 53c 08/05/22 AES Corp. backs FY22 adjusted EPS view $1.55-$1.65, consensus $1.60 08/05/22 AES Corp. reports Q2 adjusted EPS 34c, consensus 31c 21 Dec CHPT BBY AES CHPT ChargePoint $9.11 / -0.425 (-4.46%) 10/31/22 EU looks to resolve EV subsidy dispute with the U.S , Bloomberg says 10/01/22 SPAC bubble has burst, Blue Owl Luminar still have potential, Barron's says BBY Best Buy $80.22 / + (+0.00%) 08/12/22 Best Buy cuts hundreds of jobs in stores, WSJ reports AES AES Corp. $28.24 / -0.52 (-1.81%) 08/13/22 Plug Power, Sunrun among stocks for rush to renewable energy, Barron's says 07/30/22 NextEra, five others offer safety and growth now, Barron's says TERN GLYC CHPT BGNE BBY ATHA TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) 11/18/22 Biotech Alert: Searches spiking for these stocks today CHPT ChargePoint $9.11 / -0.425 (-4.46%) 12/22/22 What You Missed On Wall Street On Thursday 12/22/22 What You Missed On Wall Street This Morning 12/05/22 What You Missed On Wall Street This Morning 12/02/22 What You Missed On Wall Street On Friday BGNE BeiGene $225.27 / +5.31 (+2.41%) 11/10/22 Biotech Alert: Searches spiking for these stocks today 08/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BBY Best Buy $80.22 / + (+0.00%) 12/14/22 What You Missed On Wall Street On Wednesday 12/14/22 What You Missed On Wall Street This Morning 12/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/14/22 Fly Intel: Pre-market Movers ATHA Athira Pharma $3.34 / +0.175 (+5.54%) 09/28/22 Which Alzheimer's stock may be next to jump after Biogen's 'clean’ win? 01/04/23 JPMorgan Tech/Auto Forum 01/10/23 Transformation & Sustainability Virtual Conference 01/20/23 Extended PDUFA Date for Brukinsa 01/12/23 ChargePoint CHPT BBY AES CHPT ChargePoint $9.11 / -0.425 (-4.46%) 01/03/23 Largest borrow rate increases among liquid names 12/22/22 ChargePoint Holdings put volume heavy and directionally bearish 12/21/22 Largest borrow rate increases among liquid names 12/16/22 Unusually active option classes on open December 16th BBY Best Buy $80.22 / + (+0.00%) 11/25/22 Unusually active option classes on open November 25th 11/22/22 Early notable gainers among liquid option names on November 22nd 11/22/22 Unusually active option classes on open November 22nd 11/21/22 Best Buy put volume heavy and directionally bearish AES AES Corp. $28.24 / -0.52 (-1.81%) 12/08/22 Unusually active option classes on open December 8th 08/15/22 AES Corp. call volume above normal and directionally bullish 08/05/22 Early notable gainers among liquid option names on August 5th 08/05/22 AES Corp. call buyer realizes 130% same-day gains

Over a quarter ago
On The Fly	Biotech Alert: Searches spiking for these stocks today » 11:11 11/18/22 11/18 11:11 11/18/22 11:11 NBY NovaBay $2.11 / -0.03 (-1.40%) , FIXX Homology Medicines $1.93 / -0.08 (-3.98%) , OTIC Otonomy / + , TENX Tenax Therapeutics / + , GLYC GlycoMimetics $2.18 / +0.12 (+5.83%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings On The Fly TENX OTIC NBY GLYC FIXX TENX Tenax Therapeutics / + 10/10/22 Tenax Therapeutics announces presentation of data from study of levosimendan 09/15/22 Tenax Therapeutics trading resumes 09/15/22 Tenax Therapeutics announces evaluation of strategic alternatives 09/15/22 Tenax Therapeutics trading halted, news pending OTIC Otonomy / + 10/13/22 Otonomy's OTO-413 did not improve hearing loss in higher doses 08/01/22 Otonomy to discontinue further work on OTO-313, shift focus to OTO-413 08/01/22 Otonomy reports results from Phase 2 trial of OTO-313 NBY NovaBay $2.11 / -0.03 (-1.40%) 11/14/22 NovaBay announces 1-for-35 reverse stock split 10/18/22 NovaBay announces significant orders for DERMAdoctor Kakadu C 10/10/22 NovaBay's Avenova, DERMAdoctor to be featured in Amazon Prime sale 10/07/22 NovaBay receives NYSE American notice regarding share price GLYC GlycoMimetics $2.18 / +0.12 (+5.83%) 09/06/22 GlycoMimetics appoints Edwin Rock, M.D. as CMO FIXX Homology Medicines $1.93 / -0.08 (-3.98%) 10/27/22 Homology Medicines presents design of pheEDIT trial 09/06/22 Homology CEO Arthur Tzianabos named chairperson, Albert Seymour to succeed 07/14/22 Homology Medicines gets FDA Orphan Drug designation for MPS II treatment 07/05/22 Homology Medicines announces peer-reviewed publication on AAVHSC16 NBY FIXX OTIC TENX GLYC NBY NovaBay $2.11 / -0.03 (-1.40%) 05/20/22 Ascendiant NovaBay price target lowered to $4 from $4.25 at Ascendiant FIXX Homology Medicines $1.93 / -0.08 (-3.98%) 11/16/22 Chardan Homology Medicines price target lowered to $8 from $10 at Chardan 08/31/22 Baird Homology Medicines price target lowered to $9 from $10 at Baird 08/16/22 Chardan Homology Medicines price target lowered to $10 from $14 at Chardan 08/16/22 BTIG Homology Medicines price target lowered to $12 from $29 at BTIG OTIC Otonomy / + 10/13/22 Piper Sandler Otonomy downgraded to Neutral at Piper Sandler after OTO-413 fails 10/13/22 Piper Sandler Otonomy downgraded to Neutral from Overweight at Piper Sandler 08/02/22 H.C. Wainwright Otonomy downgraded to Neutral from Buy at H.C. Wainwright 08/01/22 Piper Sandler Otonomy price target lowered to $3 from $6 at Piper Sandler TENX Tenax Therapeutics / + 11/26/21 H.C. Wainwright Tenax operational achievements underappreciated, says H.C. Wainwright GLYC GlycoMimetics $2.18 / +0.12 (+5.83%) 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call NBY GLYC FIXX NBY NovaBay $2.11 / -0.03 (-1.40%) 11/14/22 NovaBay reports Q3 EPS (10c) vs (5c) last year GLYC GlycoMimetics $2.18 / +0.12 (+5.83%) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) 08/03/22 GlycoMimetics reports Q2 EPS (25c), consensus (28c) FIXX Homology Medicines $1.93 / -0.08 (-3.98%) 11/10/22 Homology Medicines reports Q3 EPS (59c), consensus (47c) 08/16/22 Homology Medicines reports Q2 EPS (51c), consensus (55c) TENX NBY TENX Tenax Therapeutics / + 11/07/22 Biotech Alert: Searches spiking for these stocks today NBY NovaBay $2.11 / -0.03 (-1.40%) 11/18/22 Biotech Alert: Searches spiking for these stocks today
Earnings	GlycoMimetics reports Q3 EPS (16c), consensus (26c) » 07:12 11/09/22 11/09 07:12 11/09/22 07:12 GLYC GlycoMimetics / + As of September 30,… As of September 30, GlycoMimetics had cash and cash equivalents of $51.6M as compared to $90.3M as of December 31, 2021. "Blinded pooled survival data in our pivotal Phase 3 study show patients living longer than what would be expected based on publicly available historical data. We approached the FDA as we felt an ethical obligation to conduct an interim analysis and have the independent DMC assess whether the prolonged survival observed is linked to treatment with uproleselan," said Harout Semerjian, CEO. "We are pleased the FDA is aligned with our position. Whether the DMC recommends that we continue the study as originally planned or immediately unblind for full analysis, we remain confident and excited in the potential of uproleselan to improve outcomes in relapsed/refractory AML." ShowHide Related Items >><< Company News Street Research Earnings Events GLYC GlycoMimetics / + 09/06/22 GlycoMimetics appoints Edwin Rock, M.D. as CMO GLYC GlycoMimetics / + 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call 11/12/21 Fly Intel: Top five analyst upgrades 11/12/21 Jefferies GlycoMimetics upgraded to Buy at Jefferies as AML data looked 'very promising' GLYC GlycoMimetics / + 08/03/22 GlycoMimetics reports Q2 EPS (25c), consensus (28c) 11/09/22 GlycoMimetics - GLYC
Hot Stocks	GlycoMimetics appoints Edwin Rock, M.D. as CMO » 07:03 09/06/22 09/06 07:03 09/06/22 07:03 GLYC GlycoMimetics / + GlycoMimetics announced… GlycoMimetics announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer, CMO. Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as we prepare for the readout of uproleselan's pivotal Phase 3 data in relapsed/refractory AML," said Harout Semerjian, Chief Executive Officer. "With this hire we continue to build a world-class leadership team dedicated to delivering our transformation from a research company to a commercially focused organization that improves outcomes for patients." ShowHide Related Items >><< Street Research Earnings GLYC GlycoMimetics / + 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call 11/12/21 Fly Intel: Top five analyst upgrades 11/12/21 Jefferies GlycoMimetics upgraded to Buy at Jefferies as AML data looked 'very promising' GLYC GlycoMimetics / + 08/03/22 GlycoMimetics reports Q2 EPS (25c), consensus (28c) 04/28/22 GlycoMimetics reports Q1 EPS (28c), consensus (31c)

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial